NDAORALCAPSULEPriority Review
Approved
Aug 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TURALIO (pexidartinib hydrochloride) is an oral small-molecule kinase inhibitor approved for tenosynovial giant cell tumor (TGCT), a rare benign but locally aggressive joint tumor. The drug targets colony-stimulating factor 1 receptor (CSF1R), which is implicated in the pathogenesis of TGCT. It represents a significant advance in treating a condition previously managed only through surgery.
$0.002BPart D
Peak12.1 years to LOETURALIO is in peak commercial phase with established uptake in a niche indication; teams are focused on market penetration and maintaining patient loyalty in a non-competitive space.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
Started Jan 2021
30 enrolled
HepatotoxicityTenosynovial Giant Cell Tumor
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
Started Oct 2020
32 enrolled
Tenosynovial Giant Cell Tumor
Career Relevance
TURALIO is a rare disease specialty pharma asset requiring deep expertise in orphan/niche market dynamics, patient identification, and HCP engagement in a constrained patient population. Working on TURALIO offers stability and expertise-building in rare oncology but limited exposure to large-scale commercial infrastructure or multi-indication brand management.
Worked on TURALIO at Daiichi Sankyo? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.